Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review
Original Paper
[키워드] 95% CI
95% CIs
acute kidney failure
acute renal failure
adjusted odds ratio
age
Analysis
baseline
C-reactive protein (CRP
calculate
Care
chart
clinical benefit
clinical effectiveness
Clinical outcome
cohort of patient
Comorbidities
Comorbidity
control group
control groups
COVID-19
COVID-19 diagnosis
COVID-19 pandemic
data-driven guideline
determine
dialysis
discharge
drug
Efficacy and safety
estimates
evaluate
Evidence
global pandemic
group
groups
HCQ
hospital
Hospitalization
hospitalized patient
Hydroxychloroquine
in-hospital mortality
initial
Intensive
intensive care
Invasive mechanical ventilation
mean difference
medication
multivariate logistic regression
no significant difference
objective
Odds ratio
offered
Patient
patients with COVID-19
performed
Randomized controlled trial
reduction in
reductions in
Result
retrospective cohort study
review
significantly higher
T Test
TCZ
Tocilizumab
Trial
use of hydroxychloroquine
was performed
with COVID-19
[DOI] 10.2196/21758 PMC 바로가기 [Article Type] Original Paper
[DOI] 10.2196/21758 PMC 바로가기 [Article Type] Original Paper